Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.
Nutrients. 2022 Aug 9;14(16):3256. doi: 10.3390/nu14163256.
Studies on the relationship between vitamin D (VitD) and glucose homeostasis usually consider either total VitD or 25OHD3 but not 25OHD2 and epimers. We aimed to evaluate the cross-sectional association of VitD compounds with glucose homeostasis measurements in pregnant women with overweight/obesity participating in the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus Prevention study. Methods: The analysis included 912 women. Inclusion criteria: <20 weeks gestation, body mass index ≥29 kg/m2 and information on exposure and outcome variables at baseline. Measurements: A 75 g OGTT at <20, 24−28 and 35−37 weeks gestation (except if previous diabetes diagnosis). Exposure variables: 25OHD2, 25OHD3 and C3-epimer. Outcome variables: fasting and post-challenge insulin sensitivity and secretion indices, corresponding disposition indices (DI), plasma glucose at fasting and 1 and 2 h, hyperglycemia in pregnancy (HiP). Statistics: Multivariate regression analyses with adjustment. Results: Baseline VitD sufficiency was 66.3%. Overall, VitD compounds did not show strong associations with any glucose homeostasis measures. 25OHD3 showed direct significant associations with: FPG at <20 and 24−28 weeks (standardized β coefficient (β) 0.124, p = 0.030 and 0.111, p = 0.026 respectively), 2 h plasma glucose at 24−28 weeks (β 0.120, p = 0.018), and insulin sensitivity (1/HOMA-IR, β 0.127, p = 0.027) at 35−37 weeks; it showed an inverse association with fasting DI (QUCKIHOMA-β) at <20 and 24−28 weeks (β −0.124, p = 0.045 and β −0.148, p = 0.004 respectively). 25OHD2 showed direct associations with post-challenge insulin sensitivity (Matsuda, β 0.149, p = 0.048) at 24−28 weeks) and post-challenge DI (MatsudaStumvoll phase 1) at 24−28 and 35−37 weeks (β 0.168, p = 0.030, β 0.239, p = 0.006). No significant association with C3-epimer was observed at any time period. Conclusions: In these women with average baseline VitD in sufficiency range, VitD compounds did not show clear beneficial associations with glucose homeostasis measures.
研究维生素 D（VitD）与葡萄糖稳态之间的关系通常考虑总 VitD 或 25OHD3，但不考虑 25OHD2 和差向异构体。我们旨在评估超重/肥胖孕妇体内 VitD 化合物与葡萄糖稳态测量之间的横断面关联，这些孕妇参与了维生素 D 和生活方式干预预防妊娠糖尿病研究。
分析纳入了 912 名女性。纳入标准：<20 周妊娠、身体质量指数≥29 kg/m2 以及基线时暴露和结局变量的信息。测量：<20、24-28 和 35-37 周妊娠时进行 75 g OGTT（除非之前诊断为糖尿病）。暴露变量：25OHD2、25OHD3 和 C3-差向异构体。结局变量：空腹和餐后胰岛素敏感性和分泌指数，相应的处置指数（DI），空腹和 1、2 小时的血浆葡萄糖，妊娠高血糖（HiP）。统计：调整后的多元回归分析。
基线 VitD 充足率为 66.3%。总体而言，VitD 化合物与任何葡萄糖稳态测量均无明显关联。25OHD3 与以下指标呈直接显著关联：<20 和 24-28 周的空腹血糖（标准化β系数（β）0.124，p=0.030 和 0.111，p=0.026），24-28 周的 2 小时血浆葡萄糖（β 0.120，p=0.018），35-37 周的胰岛素敏感性（1/HOMA-IR，β 0.127，p=0.027）；与<20 和 24-28 周的空腹 DI（QUCKIHOMA-β）呈负相关（β-0.124，p=0.045 和 β-0.148，p=0.004）。25OHD2 与 24-28 周的餐后胰岛素敏感性（Matsuda，β 0.149，p=0.048）和 24-28 及 35-37 周的餐后 DI（MatsudaStumvoll 阶段 1）（β 0.168，p=0.030，β 0.239，p=0.006）呈直接关联。在任何时间段都没有观察到与 C3-差向异构体的显著关联。
在这些平均基线 VitD 充足范围内的女性中，VitD 化合物与葡萄糖稳态测量没有明显的有益关联。
